Novel therapeutic strategy for intractable inflammatory disease targeting PKCeta

2016 Fiscal Year Final Research Report

• Project/Area Number: 25460153
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Drug development chemistry
• Research Institution: Showa University
• Principal Investigator: Ohba Motoi 昭和大学, 腫瘍分子生物学研究所, 講師 (70297018)
• Co-Investigator(Renkei-kenkyūsha): Shibanuma Motoko 昭和大学, 薬学部, 教授 (60245876) ; Kohno Yohko 昭和大学, 歯学部, 准教授 (40195681)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 分子標的治療 / 炎症 / PKC

Outline of Final Research Achievements

Our goal is to develop novel therapeutic methods for severe inflammatory diseases such as atopic dermatitis (AD) and arteriosclerosis targeting PKCeta. We assessed the effects of siRNA and pseudosubstrate peptide for PKCeta on AD-like dermatitis in Nc/Nga mice, model for AD. Administration of PKCeta siRNA using some transdermal delivery systems suppressed deterioration of dermatitis including itching or fissure on the back skin and ear. Moreover, novel siRNA sequences for PKCeta inhibiting its expression significantly were identified. Furthermore, we examined the effects of PKCeta gene knockout in arteriosclerosis model mice; ApoE by ApoE/PKCeta double knockout mice.

Free Research Field

細胞生物学